Literature DB >> 19834804

Circulating cytokines reflect mucosal inflammatory status in patients with Crohn's disease.

Farid Ljuca1, Adnan Gegic, Nermin N Salkic, Nada Pavlovic-Calic.   

Abstract

BACKGROUND: There is a great need for a simple activity assessment tool that can reliably predict activity in patients with Crohn's disease (CD). AIM: To investigate the relationship between serum cytokines and endoscopic activity of CD using Crohn's Disease Endoscopic Index of Severity (CDEIS) as a gold standard.
METHODS: We prospectively evaluated 32 firmly established CD patients using ileocolonoscopy, CDEIS score, and Crohn's Disease Activity Index (CDAI) score. Blood samples for cytokine analysis were obtained 1 day prior to procedure.
RESULTS: The correlation between CDEIS and CDAI was moderate (r = 0.43; P = 0.01); however, the correlation between CDEIS and inflammatory cytokines was excellent, with the highest coefficients for tumor necrosis factor alpha (TNFalpha) and interleukin-6 (IL-6) (r = 0.96 and r = 0.96, respectively; P < 0.001). CDEIS and anti-inflammatory cytokines were correlated nonlinearly (power function). We identified two separate models for predicting CDEIS value, based on the best performing pro-inflammatory [CDEIS = 0.445 x (IL-6) - 5,143] and anti-inflammatory [CDEIS = 27.478 x (IL-10)(-0.71)] cytokines. Both IL-6 and IL-10 models had high adjusted R(2) values (0.916 and 0.954, respectively). IL-6 had excellent diagnostic accuracy for detecting patients with CDEIS >7 (active disease), with area under the receiver operating characteristic (ROC) curve of 1.0 [95% confidence interval (CI) = 0.89-1.0; P < 0.001].
CONCLUSION: Serum cytokine levels are excellent predictors of endoscopic activity in patients with CD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19834804     DOI: 10.1007/s10620-009-1016-9

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  29 in total

Review 1.  Inflammatory bowel disease.

Authors:  Daniel K Podolsky
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

2.  Improved multiplex immunoassay performance in human plasma and synovial fluid following removal of interfering heterophilic antibodies.

Authors:  Wilco de Jager; Berent J Prakken; Johannes W J Bijlsma; Wietse Kuis; Ger T Rijkers
Journal:  J Immunol Methods       Date:  2005-05       Impact factor: 2.303

3.  Cytokine network in rectal mucosa in perianal Crohn's disease: relations with inflammatory parameters and need for surgery.

Authors:  Cesare Ruffolo; Marco Scarpa; Diego Faggian; Anna Pozza; Filippo Navaglia; Renata D'Incà; Pranvera Hoxha; Giovanna Romanato; Lino Polese; Giacomo Carlo Sturniolo; Mario Plebani; Davide Francesco D'Amico; Imerio Angriman
Journal:  Inflamm Bowel Dis       Date:  2008-10       Impact factor: 5.325

4.  Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives.

Authors:  R Modigliani; J Y Mary; J F Simon; A Cortot; J C Soule; J P Gendre; E Rene
Journal:  Gastroenterology       Date:  1990-04       Impact factor: 22.682

5.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

6.  Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID).

Authors:  J Y Mary; R Modigliani
Journal:  Gut       Date:  1989-07       Impact factor: 23.059

Review 7.  Review article: Crohn's disease: monitoring disease activity.

Authors:  R Sostegni; M Daperno; N Scaglione; A Lavagna; R Rocca; A Pera
Journal:  Aliment Pharmacol Ther       Date:  2003-06       Impact factor: 8.171

Review 8.  What predicts mucosal inflammation in Crohn's disease patients?

Authors:  Itta M Minderhoud; Melvin Samsom; Bas Oldenburg
Journal:  Inflamm Bowel Dis       Date:  2007-12       Impact factor: 5.325

9.  Crohn's disease in Tuzla region of Bosnia and Herzegovina: a 12-year study (1995-2006).

Authors:  Nada Pavlovic-Calic; Nermin N Salkic; Adnan Gegic; Midhat Smajic; Ervin Alibegovic
Journal:  Int J Colorectal Dis       Date:  2008-06-12       Impact factor: 2.571

10.  Evaluation of different laboratory tests and activity indices reflecting the inflammatory activity of Crohn's disease.

Authors:  A Tromm; C D Tromm; D Hüppe; U Schwegler; M Krieg; B May
Journal:  Scand J Gastroenterol       Date:  1992-09       Impact factor: 2.423

View more
  9 in total

Review 1.  Evaluation of inflammatory activity in Crohn's disease and ulcerative colitis.

Authors:  Eduardo Garcia Vilela; Henrique Osvaldo da Gama Torres; Fabiana Paiva Martins; Maria de Lourdes de Abreu Ferrari; Marcella Menezes Andrade; Aloísio Sales da Cunha
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

2.  Mitigation of Toxoplasma gondii-induced ileitis by Trichinellaspiralis infection pinpointing immunomodulation.

Authors:  Enas F Abdel Hamed; Nahed E Mostafa; Mohsen M Hassan; Mohamed N Ibrahim; Said Mahmoud Elraey; Mona Radwan; Al-Sayed R Al-Attar; Eman M Fawzy
Journal:  J Parasit Dis       Date:  2022-03-03

3.  Effect of β-Glucan Supplementation on Growth Performance and Intestinal Epithelium Functions in Weaned Pigs Challenged by Enterotoxigenic Escherichia coli.

Authors:  Yuankang Zhou; Yuheng Luo; Bing Yu; Ping Zheng; Jie Yu; Zhiqing Huang; Xiangbing Mao; Junqiu Luo; Hui Yan; Jun He
Journal:  Antibiotics (Basel)       Date:  2022-04-13

Review 4.  Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy.

Authors:  Ankit Saxena; Sam Khosraviani; Sanjeev Noel; Divya Mohan; Thomas Donner; Abdel Rahim A Hamad
Journal:  Cytokine       Date:  2014-12-04       Impact factor: 3.861

Review 5.  Why interleukin-10 supplementation does not work in Crohn's disease patients.

Authors:  Gareth J Marlow; Dominique van Gent; Lynnette R Ferguson
Journal:  World J Gastroenterol       Date:  2013-07-07       Impact factor: 5.742

Review 6.  Immunological pathogenesis of inflammatory bowel disease.

Authors:  Seung Hoon Lee; Jeong Eun Kwon; Mi-La Cho
Journal:  Intest Res       Date:  2018-01-18

7.  The Dynamics of Interleukin-10-Afforded Protection during Dextran Sulfate Sodium-Induced Colitis.

Authors:  Ana Cardoso; Antonio Gil Castro; Ana Catarina Martins; Guilhermina M Carriche; Valentine Murigneux; Isabel Castro; Ana Cumano; Paulo Vieira; Margarida Saraiva
Journal:  Front Immunol       Date:  2018-03-01       Impact factor: 7.561

8.  Evaluation of interleukin-6 and its soluble receptor components sIL-6R and sgp130 as markers of inflammation in inflammatory bowel diseases.

Authors:  Susanna Nikolaus; Georg H Waetzig; Sven Butzin; Monika Ziolkiewicz; Natalie Al-Massad; Florian Thieme; Ulf Lövgren; Birgitte B Rasmussen; Torsten M Reinheimer; Dirk Seegert; Philip Rosenstiel; Silke Szymczak; Stefan Schreiber
Journal:  Int J Colorectal Dis       Date:  2018-05-11       Impact factor: 2.571

Review 9.  The Role of the Anti-Inflammatory Cytokine Interleukin-10 in Tissue Fibrosis.

Authors:  Emily H Steen; Xinyi Wang; Swathi Balaji; Manish J Butte; Paul L Bollyky; Sundeep G Keswani
Journal:  Adv Wound Care (New Rochelle)       Date:  2020-02-07       Impact factor: 4.947

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.